Antiviral drugs combo shows promise against COVID-19

▴ antiviral-drugs-combo-shows-promise-against-covid19
Treatment involving a combination of the drugs interferon beta-1b, plus antiviral therapy lopinavir-ritonavir and ribavirin, is better at reducing the viral load.

According to the researchers, including those from the University of Hong Kong, treatment involving a combination of the drugs interferon beta-1b, plus the antiviral therapy lopinavir-ritonavir and ribavirin, is better at reducing the viral load than lopinavir-ritonavir alone.
Larger phase 3 trials to examine the effectiveness of this triple combination in critically ill patients, adding that these early findings were only observed in patients with mild to moderate illness are the need of the hour
Based on earlier studies on influenza, in which patients have high quantities of the virus in their bodies when the symptoms begin to appear, they said treating hospitalised patients with a combination of multiple antiviral drugs may be more effective than single-drug treatments.
According to the researchers, this may minimise the risk of antiviral resistance and can be used as a possible therapeutic approach for COVID-19, in which the viral load also peaks around the time of symptom onset.
“Our trial demonstrates that early treatment of mild to moderate COVID-19 with a triple combination of antiviral drugs may rapidly suppress the amount of virus in a patient’s body, and relieve symptoms by reducing the duration and quantity of viral shedding,” said study co-author Kwok-Yung Yuen from the University of Hong Kong.
“These findings suggest that interferon beta 1-b may be a key component of the combination treatment and is worth further investigation for the treatment of COVID-19”, said Jenny Lo, co-author of the study from Ruttonjee Hospital in Hong Kong.
The researchers believe that a future phase 3 trial will confirm or refute the usefulness of this candidate drug as a backbone treatment for COVID-19.
They also said the findings may be confounded by the subgroup of 34 patients within the combination group who were admitted seven days or more after symptom onset, and were not offered interferon beta-1b, but were analysed as part of the combination group.

Tags : #Medicircle #HongKong #COVID-19 #Antiviral

About the Author


Stuti

Btech. Computer Science
MBA aspirant
Preparing for GMAT currently
Interests: AI, writing and books

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

US has biggest COVID-19 testing programmeJuly 14, 2020
NHPC organizes blood donation camp to support blood banks July 14, 2020
Studies predicts surge in HIV, TB, and Malaria deaths due to COVID-19July 14, 2020
AIIMS Patna starts human trial of Coronavirus vaccineJuly 14, 2020
World’s population likely to shrink after mid-century : LancetJuly 14, 2020
21 deaths, 1,654 fresh Covid-19 cases in UP; total count 38,130July 14, 2020
Over 90 doctors have died so far IMAJuly 14, 2020
Glenmark cuts price of Covid-19 drug Favipiravir version to $1 per tabJuly 14, 2020
19 States, UTs report higher recovery rate than national average of 63%July 14, 2020
Govt advises cautious use of Remdesivir, Tocilizumab for Covid-19 July 13, 2020
Govt in process of selecting 3 bulk drug and 4 medical devices parkJuly 13, 2020
Glenmark commences 1000 patients surveillance study ; FabiFluJuly 13, 2020
Neuherbs enters in sanitation category, launches sub-brand NeusafeJuly 13, 2020
Thailand gears up for human trials for their COVID-19 vaccineJuly 13, 2020
How the world's busiest airport envisions travel amid COVID-19July 13, 2020
Mexico coronavirus death count risesJuly 13, 2020
Florida sets 1-day record of new COVID-19 casesJuly 13, 2020
Russian University claims successful trials of 1st COVID-19 vaccineJuly 13, 2020
Over 5,53000 recovered so far: COVID recovery rate reaches 63.01%July 13, 2020
Bihar reports largest ever spike with 1266 COVID cases in last 24 hrsJuly 13, 2020